Nicholas DeVito: Understanding Dendritic Cells to Improve Cancer Immunotherapy
Nicholas DeVito, Assistant Professor of Medicine at the Division of Medical Oncology at Duke University, shared a post on LinkedIn about a paper by Degao Chen et al. published in Cancer Cell:
“Dendritic cells (DCs) continue to amaze us with their repertoire of talents!
Beyond determining self vs non-self via antigen presentation and tolerance mechanisms as well as coordinating communication with a myriad of other cells in the immune system, we now know that DCs can degrade neutrophil extracellular traps (NETs) with DNAse to facilitate immune checkpoint inhibitor activity.
NETs are produced by immune suppressive neutrophils, often termed myeloid-derived suppressor cells, in tumors and pre-metastatic niches where they promote the outgrowth of metastasis. DCs can surveil tumors and metastasis by degrading these NETs and taking up tumor antigens to present in the lymph node.
A better understanding of DC biology in cancer and determinants of DC phenotype will expand our ability to treat more patients with immunotherapy.”
Title: DNASE1L3-expressing dendritic cells promote CD8+ T cell function and anti-PD-(L)1 therapy efficacy by degrading neutrophil extracellular traps
Authors: Degao Chen, Zheng Jin, Han Chu, Yucui Wu, Yangping Bian, Ting Yuan, Hao Lv, Qiuyu Xia, Lei Wang, Qian Chu, Quanxing Liu, Dong Zhou, Wenfeng Fang, Xiaoming Cheng, Haoran Zha, Haixia Long, Li Zhang, Jigang Dai, Yisong Y. Wan, Qi-Jing Li, Qingzhu Jia, Xindong Liu, Bo Zhu
You can read the Full Article on Cancer Cell.
More posts featuring Nicholas DeVito.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023